title: Intravitreal aflibercept for rubeosis iridis secondary to proliferative diabetic retinopathy.
abstract: The purpose of this article is to report a case with rubeosis iridis treated by intravitreal aflibercept. A 61-year-old man had iris neovascularization and scanty vitreous hemorrhage secondary to proliferative diabetic retinopathy in the right eye. Neither neovascularization of angle nor elevation of intraocular pressure was found. Single intravitreal aflibercept 2 mg injection was performed. Rubeosis iridis disappeared on the next day. Scattered retinal laser photocoagulation was added 1 week later. There was no recurrence after 3-month follow-up. Aflibercept may serve as another anti-vascular endothelial growth factor (anti-VEGF) for treating rubeosis iridis.
authors.forename: Shao-Wei
authors.initials: SW
authors.lastname: Weng
authors.forename: Tzu-Lun
authors.initials: TL
authors.lastname: Huang
authors.forename: Pei-Yuan
authors.initials: PY
authors.lastname: Su
authors.forename: Pei-Yao
authors.initials: PY
authors.lastname: Chang
authors.forename: Jia-Kang
authors.initials: JK
authors.lastname: Wang
mesh_terms: D003930:Diabetic Retinopathy / Q000150:complications*; D006801:Humans; D058449:Intravitreal Injections; D007498:Iris / Q000098:blood supply*; D028022:Low-Level Light Therapy / Q000379:methods; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000209:etiology; D040262:Receptors, Vascular Endothelial Growth Factor / Q000008:administration & dosage*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014823:Vitreous Hemorrhage / Q000209:etiology
chemical_list: D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor